Kejing Tang

机构：Sun Yat-sen University, The First Affiliated Hospital, Sun Yat-sen University · ORCID：0000-0002-5454-4666

发表论文 241 篇 · 总被引 4247 次 · h-index 32

代表论文

• Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial (2025 · The Lancet · 被引 35)
• Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B) (2025 · Journal of Clinical Oncology · 被引 17)
• Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial (2025 · The Lancet Respiratory Medicine · 被引 10)
• Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation (2025 · Cell Reports Medicine · 被引 4)
• Sosimerasib monotherapy in patients with previously treated KRAS G12C–mutated non-small cell lung cancer: Primary results of a phase 2 study. (2025 · Journal of Clinical Oncology · 被引 3)
• AML1-ETO and CCND2 overexpression cooperate to drive acute myeloid leukemia initiation and progression (2025 · Journal of Leukocyte Biology · 被引 3)